-+ 0.00%
-+ 0.00%
-+ 0.00%

DBV Technologies launches Phase 2 THRIVE trial of Viaskin Peanut Patch in peanut-allergic infants 6-12 months

PUBT·06/08/2026 20:35:23
Listen to the news
DBV Technologies launches Phase 2 THRIVE trial of Viaskin Peanut Patch in peanut-allergic infants 6-12 months
  • DBV Technologies flagged new positive Phase 3 VITESSE subgroup results for its VIASKIN Peanut Patch, scheduled for presentation at EAACI Congress 2026.
  • The analysis showed the patch outperformed placebo in children with peanut allergy who also had common atopic comorbidities.
  • DBV also previewed the recently initiated Phase 2 THRIVE trial in infants aged 6–12 months, with data to be presented at EAACI 2026.
  • THRIVE aims to assess whether three years of treatment can enable ad lib peanut consumption, supporting an earlier-intervention strategy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606081635PRIMZONEFULLFEED1001186596) on June 08, 2026, and is solely responsible for the information contained therein.